A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

NCT07709715 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Light Chain (AL) Amyloidosis

Interventions

BIOLOGICAL: NXC-201
DRUG: Dara-CyBorD

Sponsor

Nexcella Inc.

Collaborators

[object Object]